Medical Treatment of Female Sexual Dysfunction.
Androgens
Estrogens
Female sexual dysfunction
Genitourinary syndrome of menopause
Hypoactive sexual desire disorder
Psychoactive drugs
Vasoactive drugs
Journal
The Urologic clinics of North America
ISSN: 1558-318X
Titre abrégé: Urol Clin North Am
Pays: United States
ID NLM: 0423221
Informations de publication
Date de publication:
May 2022
May 2022
Historique:
entrez:
16
4
2022
pubmed:
17
4
2022
medline:
20
4
2022
Statut:
ppublish
Résumé
Female sexual dysfunction (FSD) comprises multiple overlapping sexual disorders with a multifaceted cause within the frame of the biopsychosocial model. Health care providers can screen for FSD according to their level of expertise and deliver at least basic counseling before eventually referring to sexual medicine specialists for specific care. The therapeutic algorithm comprises a multidisciplinary approach, including pharmacologic and nonpharmacologic management. Flibanserin and bremelanotide are psychoactive agents indicated for the treatment of generalized acquired hypoactive sexual desire disorder (HSDD) in premenopausal women, whereas transdermal testosterone is effective on HSDD in postmenopausal women. Menopause hormone therapy (systemic and local) is the mainstay for individualized management of women at midlife.
Identifiants
pubmed: 35428435
pii: S0094-0143(22)00004-0
doi: 10.1016/j.ucl.2022.02.001
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
299-307Informations de copyright
Copyright © 2022 Elsevier Inc. All rights reserved.